ESCRS - POCAT076 - Long-Term Outcomes With An Extended Macular Iol In Eyes With Age-Related Macular Degeneration: A Longitudinal Case Series

Long-Term Outcomes With An Extended Macular Iol In Eyes With Age-Related Macular Degeneration: A Longitudinal Case Series

Published 2026 - 44th Congress of the ESCRS

Reference: POCAT076 | Type: Case Report | DOI: 10.82333/0zvb-zp54

Authors: Dr Tabitha Neuhann* 1 , Dr Tobias Neuhann 1

1Ophthalmologikum Dr.Neuhann MVZ GmbH,Munich,Germany

Purpose

To describe long-term functional and structural outcomes after implantation of the EyeMax Mono extended macular vision (EMV) intraocular lens (IOL) in eyes with age-related macular degeneration (AMD) using spectral-domain optical coherence tomography (OCT) and corrected distance visual acuity (CDVA).

Setting

Retrospective longitudinal single-center case series

Report of case

Methods:
This study included eyes with dry or exudative AMD that underwent cataract surgery with the EyeMax Mono IOL. CDVA was anchored at 1 month postoperatively to establish a post-cataract functional baseline and reduce confounding from lens extraction. Spectral-domain OCT, obtained at the same visits as CDVA, was qualitatively graded for disease activity and structural biomarkers, including intraretinal fluid (IRF), subretinal fluid (SRF), pigment epithelial detachment (PED), subretinal hyperreflective material (SHRM), and the presence of atrophy or fibrosis. Eyes with at least three OCT examinations, including baseline and ≥1 visit at ≥12 months, were included. Given variable follow-up, outcomes were analyzed descriptively on a per-eye basis.
 
Results: 
25 IOLs were implanted while five eyes from four patients (mean age 84 years) met the inclusion criteria, including one eye with dry AMD and four with exudative AMD. From the 1-month postoperative baseline, CDVA improved in one eye over 12 months (logMAR 0.7 to 0.4), remained stable in one eye with dry AMD over 36 months, and declined in three eyes with exudative AMD at final follow-up. Eyes with stable or improved CDVA showed relative structural stability on OCT, whereas eyes with visual decline demonstrated features consistent with ongoing disease activity or progressive atrophic or fibrotic changes. Two eyes required ongoing intravitreal therapy during follow-up

Conclusion/Take home message

In this small longitudinal case series, EyeMax Mono IOL implantation was associated with stable or improved CDVA in a subset of eyes with AMD, while visual decline in others appeared primarily driven by progression of exudative disease and structural retinal damage on OCT. Larger prospective studies with standardized functional and imaging endpoints are warranted.